AgingResearch.NewsJoin free

Prasugrel

Prasugrel has been studied in 6 papers since 2016: 1 trial and 1 observational study in people, 1 in animals, 3 reviews. The newest paper, Sep 26, 2025: “Memory deficits in hypertensive ApoE4 mice reversed by P2Y12 inhibition via different mechanisms in males and perimenopausal females”.

Intervention

6 papers study it2 more mention it5 findingsUpdated

PubChemChEBIMeSH

See all 8

“Pras 5 mg reduced both ADP-stimulated platelet P-selectin and activated GPIIb-IIIa in VE (p < 0.01 for both analyses)”
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patientsJournal of thrombosis and thrombolysis2016doi:10.1007/s11239-016-1372-1

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 2 independent labs in 2 countries
  • 24 trials, none about aging, 1 with no results posted
  • Funders: Cure Alzheimer’s Fund and 7 more
  • 2 of 5 findings with company ties
  • 14 of 24 trials sponsored by its developers
  • Human trial1
  • Humans1
  • Animals1

Studies in people

1 study gave prasugrel to people and measured what changed.

  • down: Decreases P-selectinp < 0.01 in very elderly; p < 0.001 in non-elderly

    down: Decreases platelet activationp < 0.01

    Randomized trial23 peoplevery elderly (78 ± 5 years) and non-elderly (55 ± 5 years)12-day period

    Midlife adults; Older adults; ADP-stimulated platelets; also reduced in non-elderly (p < 0.001)

    Journal of thrombosis and thrombolysis, May 12, 2016

What did studies of Prasugrel find?

5

Studies of Prasugrel measured 5 outcomes; the most studied are microglia motility (1 study), cerebral blood flow (1) and memory performance (1).

Microglia motility

downin mice1

1 study

  1. Prasugrel decreases microglia motility in peri-AOF females.

    “reduced microglia motility and inflammation in peri-AOF females”

    Animalsin peri-AOF femalesfemales

    Memory deficits in hypertensive ApoE4 mice reversed by P2Y12 inhibition via different mechanisms in males and perimenopausal females

    Research squarePreprint

More on Microglia motility

Cerebral blood flow

upin mice1

1 study

  1. Prasugrel increases cerebral blood flow in hypertensive ApoE4 mice treated with prasugrel.

    “restored cerebral blood flow in males”

    Animalsin hypertensive ApoE4 mice treated with prasugrelmales

    Memory deficits in hypertensive ApoE4 mice reversed by P2Y12 inhibition via different mechanisms in males and perimenopausal females

    Research squarePreprint

Memory performance

upin mice1

1 study

  1. Prasugrel improves memory performance in hypertensive ApoE4 mice.

    “Treatment with prasugrel, a P2Y12 receptor inhibitor, improved memory performance in both sexes”

    Animalsin hypertensive ApoE4 mice

    Memory deficits in hypertensive ApoE4 mice reversed by P2Y12 inhibition via different mechanisms in males and perimenopausal females

    Research squarePreprint

Platelet activation

downin humans1

1 study

  1. Prasugrel decreases platelet activation in humans (compared with clopidogrel 75 mg) (p < 0.01).

    “Prasugrel 10 mg resulted in decreased platelet activation in both age groups compared to Clop 75 mg (p < 0.01).”

    Human trialcompared with clopidogrel 75 mgplatelets10 mg12-day period

    Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients

    Journal of thrombosis and thrombolysis

P-selectin

downin humans1

1 study

  1. Prasugrel decreases P-selectin in humans (ADP-stimulated platelets; also reduced in non-elderly (p < 0.001)) (p < 0.01 in very elderly; p < 0.001 in non-elderly).

    “Pras 5 mg reduced both ADP-stimulated platelet P-selectin and activated GPIIb-IIIa in VE (p < 0.01 for both analyses)”

    Human trialADP-stimulated platelets; also reduced in non-elderly (p < 0.001)platelets5 mg12-day periodn = 23

    Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients

    Journal of thrombosis and thrombolysis

More on P-selectin

Who is developing Prasugrel?

1 company: Viatris Innovation.

Companies

Trial sponsors

Latest

Related